ホーム › 悪性黒色腫 › テネシー › Nashville
Nashville、TNにおける悪性黒色腫の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する33件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Tennessee Oncology, Nashville
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study of BI 3810944 in Patients With Advanced Cancer
被験者募集中第1相
- Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
被験者募集中第3相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
被験者募集中第3相
- SCRI Oncology Partners, Nashville
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
被験者募集中第3相
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology, PLLC, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
被験者募集中第1相
- Tennessee Oncology, Nashville
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
被験者募集中第1/2相
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
被験者募集中
- Vanderbilt-Ingram Cancer Center, Nashville
Neoadjuvant Darovasertib in Primary Uveal Melanoma
被験者募集中第3相
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
被験者募集中第1相
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
被験者募集中観察研究
- Vanderbitl-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Pittsburgh, PA31件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Columbus, OH21件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- Salt Lake City, UT21件の研究
- St. Louis, MO21件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。